ROCKVILLE, Md., April 19 /PRNewswire/ -- Protiveris Inc., a
bio-nanotechnology company commercializing microcantilever technologies to
facilitate biomolecular research, today announced the appointment of Gregory
Kellogg Ph.D. as Chief Technology Officer.
"I am very pleased to welcome Greg to the Protiveris management team. He
has been key in building the success of several groundbreaking biotechnology
companies, including Network Biosystems and Tecan Boston," said Robert Menzi,
Chief Operating Officer at Protiveris. "Greg's skill and depth of experience
complement our existing management strengths and we look forward to his
contribution to the further development and commercialization of our VeriScan
Dr. Kellogg brings to Protiveris a strong history of innovation in
developing technology and building R&D organizations. Formerly Vice President
of Research at Network Biosystems, Dr Kellogg managed the development of a
microfabrication-based electrophoresis system for forensic applications. Prior
positions include Director of R&D at IQUUM, where he planned and executed
product development feasibility programs, and Chief Scientist at Tecan Boston
(formerly Gamera Bioscience Corporation), where he developed the technical
foundation of the company's microfluidic platform. This technology was
introduced into the drug discovery marketplace as the LabCD(TM), an
automation-compatible system for ADMET. Dr. Kellogg received his Ph.D. in
physics from Harvard University and conducted his post-doctoral research at
Massachusetts Institute of Technology in the Department of Materials Science
and Engineering. He has published extensively and is an inventor on more than
10 issued US and European patents.
About Protiveris, Inc.
Protiveris is committed to establishing the standard of performance for
proteomic research tools. The VeriScan(TM) 3000 bench-top biochip system
measures and analyzes biomolecular and chemical interactions to enable more
efficient and accurate research outcomes. The biochip utilizes arrays of
microcantilevers with customizable surfaces to detect interactions between
proteins, antibodies, antigens, or DNA. This label-free system provides
researchers with the ability to create high content assays that deliver real
time data. More information about Protiveris, their technology, products, and
services can be found at the company's web site at http://www.protiveris.com .
SOURCE Protiveris Inc.